Women Health Expert GC-Rise Launches Obstetrician-gynecologist Prize

BEIJING, July 31, 2012 /PRNewswire-Asia/ -- GC-Rise Pharmaceutical Co. Ltd, in which European healthcare venture capital firm INVENTAGES holds a majority stake, has launched an obstetrician-gynecologist Honorary Award given to those who have done outstanding achievement in the medical community.

The company on July 15 held the first-ever GC-Rise-Cup ceremony in Hefei, capital city of central China's Anhui province, where awards were presented to 20 obstetrician-gynecologists chosen from around the country.

The 20 final award-winners stood out among 70 candidates after six months' open and fair appraisals by the selection committee.

The winners, with an average age of 80, include the expert who did the first test-tube baby in China, the doctor who was the first to advocate the importance of maternal and infant care and the one who was the first to promote the idea of painless delivery.

The prize, which compares to the 'OSCAR' in the medical industry, was jointly initiated by GC-Rise and China Medical Doctor Association, and is the first-ever and only award pointing to individuals in the medical circle in China.

The move aims to encourage the younger generations to inherit the spirits of the seniors, which shows GC-Rise's consistent commitment to play an active part in the women's health industry by joining hands with experts and professionals in the circle.

About GC-Rise Pharmaceutical Co. Ltd

GC-Rise Pharmaceutical Co. Ltd, established in 2008, is a wholly-owned foreign enterprise invested by INVENTAGES, a major European healthcare and biotechnology venture capital investor, focuses on women's health. Taking "Devoted to human healthcare and a better life" as our mission, the company makes full use of the business networks of our strategic partners in the United States, Europe and Japan, their rich experiences in clinical development, clinical trials and registration in China and their strong strength in distributions, hospital sales and marketing, so as to provide safe, novel and highly efficient medical products and treatment ideas for Chinese women patients.

Please log on http://www.gc-rise.com/ to know more information.


SOURCE GC-Rise Pharmaceutical Co. Ltd

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.